The Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling
pathway was discovered more than a quarter-century ago. As a fulcrum of many vital cellular …

Chemotherapy is one of the most common treatments for cancer that uses one or more anti-
cancer drugs as a part of the standardized chemotherapy regimen. Cytotoxic chemicals …

Inflammatory conditions represent the largest class of chronic skin disease, but the
molecular dysregulation underlying many individual cases remains unclear. Single-cell RNA …

Background Upadacitinib is an oral Janus kinase (JAK) inhibitor with greater inhibitory
potency for JAK1 than JAK2, JAK3, and tyrosine kinase 2. We aimed to assess the efficacy …

Abrocitinib (Cibinqo®) is an oral small-molecule inhibitor of Janus kinase 1 (JAK1) being
developed by Pfizer for the treatment of moderate-to-severe atopic dermatitis (AD). In …

Atopic dermatitis (AD) is a chronic, heterogenous, inflammatory skin disorder associated
with a high skin‐related health burden, typically starting in childhood and often persisting …

In recent years, the broadening understanding of the pathogenesis of atopic dermatitis (AD)
has led to the development of novel therapeutic molecules, that target core inflammatory …

Atopic dermatitis (AD) patients are massively colonized with Staphylococcus aureus (S.
aureus) in lesional and non-lesional skin. A skin infection may become systemic if left …

Atopic dermatitis (AD) is one of the most prevalent inflammatory disease among non-fatal
skin diseases, affecting up to one fifth of the population in developed countries. AD is …

Despite the recent emergence of targeted therapeutic options, there are still unmet needs
concerning moderate-to-severe atopic dermatitis treatment. This review aims to discuss the …